Biontech Cell&gene Therapies competitive analysis

Loading summary...

Explore Biontech Cell&gene Therapies's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jul 9, 2025Claudin-18.2-Specific Immunoreceptors And T Cell Epitopes1
Jul 26, 2023Enhancing The Effect Of Car-Engineered T Cells By Means Of Nucleic Acid Vaccination1
Feb 16, 2022Claudin-6-Specific Immunoreceptors And T Cell Epitopes1

Latest publications and patents of Biontech Cell&gene Therapies New

Explore the latest publications and patents granted to Biontech Cell&gene Therapies, showcasing their recent innovations and technological advancements.

Last updated on: Oct 17, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Biontech Cell&gene Therapies

Jul 9, 2025Claudin-18.2-Specific Immunoreceptors And T Cell EpitopesPatent Maintained As Amended
Jul 26, 2023Enhancing The Effect Of Car-Engineered T Cells By Means Of Nucleic Acid VaccinationGranted And Under Opposition
Feb 16, 2022Claudin-6-Specific Immunoreceptors And T Cell EpitopesPatent Maintained As Amended

Latest PTAB cases involving Biontech Cell&gene Therapies

Discover the latest PTAB cases involving Biontech Cell&gene Therapies, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Biontech Cell&gene Therapies with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIONTECH CELL&GENE THERAPIES - 3 - -
DR H ULRICH DORRIES26 - - -
SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBB22 - - -
WITHERS & ROGERS33 - - -